These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24671226)

  • 21. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
    Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
    Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
    Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H
    Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
    Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
    Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution pattern of Ki67 immunoreactivity in ductal intraepithelial neoplasia: Correlation with lesion grade and potential utility.
    Ozerdem U; Tavassoli FA
    Pathol Res Pract; 2016 Oct; 212(10):872-875. PubMed ID: 27499154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diagnostic utility of EZH2 H-score and Ki-67 index in non-invasive breast apocrine lesions.
    Vougiouklakis T; Belovarac BJ; Lytle A; Chiriboga L; Ozerdem U
    Pathol Res Pract; 2020 Sep; 216(9):153041. PubMed ID: 32825929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of cyclins in ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
    Kim HJ; Jung WH; Kim DY; Lee HD
    Yonsei Med J; 2000 Jun; 41(3):345-53. PubMed ID: 10957889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
    Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
    Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinic-Pathological Features of Breast Ductal Carcinoma
    Zheng J; Zhou T; Li F; Shi J; Zhang L
    Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
    [No Abstract]   [Full Text] [Related]  

  • 30. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions.
    Liu TT; Li XF; Wang L; Yang JL
    Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
    Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
    Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
    Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
    Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer].
    Pan XY; Wu JK; Lang ZQ; Qu L; Jiang L
    Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):838-842. PubMed ID: 36097899
    [No Abstract]   [Full Text] [Related]  

  • 34. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues.
    Bozkurt KK; Kapucuoğlu N
    Pathol Res Pract; 2012 Mar; 208(3):133-9. PubMed ID: 22336175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low Expression of Estrogen Receptor-α and Progesterone Receptor in Human Breast Cancer Tissues Is Associated With High-Grade Human Cytomegalovirus Protein Expression.
    Rahbar A; Touma J; Costa H; Davoudi B; Bukholm IR; Sauer T; Vetvik K; Geisler J; Söderberg-Naucler C
    Clin Breast Cancer; 2017 Nov; 17(7):526-535.e1. PubMed ID: 28595965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
    Nakamura R; Oyama T; Inokuchi M; Ishikawa S; Hirata M; Kawashima H; Ikeda H; Dobashi Y; Ooi A
    Pathol Int; 2020 Jun; 70(6):330-339. PubMed ID: 32103597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
    Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
    Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.